share_log

Chardan Capital Maintains Buy on Senti Biosciences, Lowers Price Target to $6

Chardan Capital Maintains Buy on Senti Biosciences, Lowers Price Target to $6

Chardan Capital维持对Senti Biosciences的买入,将目标股价下调至6美元
Benzinga ·  2023/05/11 13:08

Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and lowers the price target from $7 to $6.

Chardan Capital分析师Geulah Livshits维持Senti Biosciences(纳斯达克股票代码:SNTI)的买入,并将目标股价从7美元下调至6美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发